Paper34813613
Correlates of survival after autoantibody reduction therapy for acute IPF exacerbations.
Kulkarni T and 10 others. PLoS One, 2021. Cited by 17 papers, by iCite.
Cite this record
ConductScience Library. Correlates of survival after autoantibody reduction therapy for acute IPF exacerbations. Papers, record 34813613. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/34813613
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Idiopathic Pulmonary Fibrosis | Major topic |
| Immunoglobulins, Intravenous | Major topic |
| Immunologic Factors | Major topic |
| Plasma Exchange | Major topic |
| Rituximab | Major topic |
| Acute Disease | |
| Aged | |
| Autoantibodies | |
| Female | |
| Humans | |
| Male | |
| Prospective Studies |
Source PubMed
Grants2
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| T32 HL105346 | NHLBI NIH HHS | United States | T32HL105346 | PubMed | NIH RePORTER |
| U01 HL133232 | NHLBI NIH HHS | United States | U01HL133232 | PubMed | NIH RePORTER |
References42
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23171098 | Intravenous immune globulin in autoimmune and inflammatory diseases. | N Engl J Med | 2012 | https://conductscience.org/library/papers/23171098 | PubMed |
| 2 | 10871435 | Elevation of anti-cytokeratin 18 antibody and circulating cytokeratin 18: anti-cytokeratin 18 antibody immune complexes in sera of patients with idiopathic pulmonary fibrosis. | Lung | 2000 | https://conductscience.org/library/papers/10871435 | PubMed |
| 3 | 24107778 | BPIFB1 is a lung-specific autoantigen associated with interstitial lung disease. | Sci Transl Med | 2013 | https://conductscience.org/library/papers/24107778 | PubMed |
| 4 | 20077121 | Advances in diagnosing and managing antibody-mediated rejection. | Pediatr Nephrol | 2010 | https://conductscience.org/library/papers/20077121 | PubMed |
| 5 | 19204770 | Removal kinetics of therapeutic apheresis. | Blood Transfus | 2007 | https://conductscience.org/library/papers/19204770 | PubMed |
| 6 | 17585107 | Acute exacerbations of idiopathic pulmonary fibrosis. | Am J Respir Crit Care Med | 2007 | https://conductscience.org/library/papers/17585107 | PubMed |
| 7 | 24628285 | C-X-C motif chemokine 13 (CXCL13) is a prognostic biomarker of idiopathic pulmonary fibrosis. | Am J Respir Crit Care Med | 2014 | https://conductscience.org/library/papers/24628285 | PubMed |
| 8 | 11694958 | Autoantibodies to IL-1 alpha in sera from rapidly progressive idiopathic pulmonary fibrosis. | J Med Invest | 2001 | https://conductscience.org/library/papers/11694958 | PubMed |
| 9 | 27159038 | Immune Inflammation and Disease Progression in Idiopathic Pulmonary Fibrosis. | PLoS One | 2016 | https://conductscience.org/library/papers/27159038 | PubMed |
| 10 | 11467755 | Treatment of autoimmune disease: synergy between plasma exchange and intravenous immunoglobulins. | Ther Apher | 2001 | https://conductscience.org/library/papers/11467755 | PubMed |
| 11 | 25441030 | B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis. | J Autoimmun | 2015 | https://conductscience.org/library/papers/25441030 | PubMed |
| 12 | 26160873 | An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. | Eur Respir J | 2015 | https://conductscience.org/library/papers/26160873 | PubMed |
| 13 | 22282550 | Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. | Eur Respir J | 2012 | https://conductscience.org/library/papers/22282550 | PubMed |
| 14 | 21373184 | The HLA class II Allele DRB1*1501 is over-represented in patients with idiopathic pulmonary fibrosis. | PLoS One | 2011 | https://conductscience.org/library/papers/21373184 | PubMed |
| 15 | 28356570 | Idiopathic pulmonary fibrosis and a role for autoimmunity. | Immunol Cell Biol | 2017 | https://conductscience.org/library/papers/28356570 | PubMed |
| 16 | 28754682 | Autoimmunity to Vimentin Is Associated with Outcomes of Patients with Idiopathic Pulmonary Fibrosis. | J Immunol | 2017 | https://conductscience.org/library/papers/28754682 | PubMed |
| 17 | 17108669 | Inflammatory cell phenotyping of the pulmonary interstitium in idiopathic interstitial pneumonia. | Respiration | 2007 | https://conductscience.org/library/papers/17108669 | PubMed |
| 18 | 20595144 | Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. | Eur Respir J | 2011 | https://conductscience.org/library/papers/20595144 | PubMed |
| 19 | 12209492 | Evidence-based guidelines for the use of immunologic tests: antinuclear antibody testing. | Arthritis Rheum | 2002 | https://conductscience.org/library/papers/12209492 | PubMed |
| 20 | 27299520 | Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. | Am J Respir Crit Care Med | 2016 | https://conductscience.org/library/papers/27299520 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 17 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42447235 | Acute exacerbation in fibrotic interstitial lung disease: an international working group report. | Am J Respir Crit Care Med | 2026 | https://conductscience.org/library/papers/42447235 | PubMed |
| 41470099 | Acute Exacerbation of Interstitial Lung Disease: Early Diagnosis and Treatment. | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/41470099 | PubMed |
| 40604645 | Machine learning-based integration identifies plasma cells-related gene signature ST6GAL1 in idiopathic pulmonary fibrosis. | BMC Pulm Med | 2025 | https://conductscience.org/library/papers/40604645 | PubMed |
| 40124525 | The Intersection between Immune System and Idiopathic Pulmonary Fibrosis-A Concise Review. | Fibrosis (Hong Kong) | 2025 | https://conductscience.org/library/papers/40124525 | PubMed |
| 39737178 | The immune mechanisms of acute exacerbations of idiopathic pulmonary fibrosis. | Front Immunol | 2024 | https://conductscience.org/library/papers/39737178 | PubMed |
| 39403408 | Understanding myofibroblast origin in the fibrotic lung. | Chin Med J Pulm Crit Care Med | 2024 | https://conductscience.org/library/papers/39403408 | PubMed |
| 39144320 | Acute exacerbation of idiopathic pulmonary fibrosis a narrative review primary focus on treatments. | J Thorac Dis | 2024 | https://conductscience.org/library/papers/39144320 | PubMed |
| 38869027 | Pharmacological treatment in Idiopathic Pulmonary Fibrosis: current issues and future perspectives | Multidiscip Respir Med | 2024 | https://conductscience.org/library/papers/38869027 | PubMed |
| 38509495 | Design of the STRIVE-IPF trial- study of therapeutic plasma exchange, rituximab, and intravenous immunoglobulin for acute exacerbations of idiopathic pulmonary fibrosis. | BMC Pulm Med | 2024 | https://conductscience.org/library/papers/38509495 | PubMed |
| 38465342 | Role of serum B-cell-activating factor and interleukin-17 as biomarkers in the classification of interstitial pneumonia with autoimmune features. | Open Life Sci | 2024 | https://conductscience.org/library/papers/38465342 | PubMed |
| 37673443 | Rituximab for the treatment of acute exacerbation of interstitial lung disease associated with connective tissue disease. | RMD Open | 2023 | https://conductscience.org/library/papers/37673443 | PubMed |
| 36004373 | Clinical relevance of circulating autoantibodies in idiopathic pulmonary fibrosis; A NAt hard to break. | Front Med (Lausanne) | 2022 | https://conductscience.org/library/papers/36004373 | PubMed |
Genes8
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ALB | 213 | PubTator's text mining | https://conductscience.org/library/genes/213 | NCBI Gene |
| CXCL13 | 10563 | PubTator's text mining | https://conductscience.org/library/genes/10563 | NCBI Gene |
| F8 | 2157 | PubTator's text mining | https://conductscience.org/library/genes/2157 | NCBI Gene |
| FGB | 2244 | PubTator's text mining | https://conductscience.org/library/genes/2244 | NCBI Gene |
| HSPA4 | 3308 | PubTator's text mining | https://conductscience.org/library/genes/3308 | NCBI Gene |
| NEUROG1 | 4762 | PubTator's text mining | https://conductscience.org/library/genes/4762 | NCBI Gene |
| TNFSF13 | 8741 | PubTator's text mining | https://conductscience.org/library/genes/8741 | NCBI Gene |
| TNFSF13B | 10673 | PubTator's text mining | https://conductscience.org/library/genes/10673 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/34813613
GET https://conductscience.org/api/papers/v1/34813613/references?page=2